2017
DOI: 10.1016/j.pt.2016.11.003
|View full text |Cite
|
Sign up to set email alerts
|

Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs

Abstract: New drugs are needed to control leishmaniasis and efforts are currently on-going to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be conf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
82
0
5

Year Published

2017
2017
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 105 publications
(92 citation statements)
references
References 79 publications
1
82
0
5
Order By: Relevance
“…The results from this study were used as a basis for the development of a L. donovani genotyping methodology in Nepal and permitted an association to be made between the Leishmania genotype and the treatment applied to the patients (Rai et al, 2017). It might also be useful in identifying new drugs against leishmaniasis (Hefnawy et al, 2016). Although these studies have successfully examined intra-species genomic diversity and genes associated with visceral versus non-visceral forms of disease, an analysis of Leishmania genomes associated with different host phenotypes within a species is required to reveal possible sequence signatures or genomic structural markers associated with diverse clinical manifestations or potential host specificity.…”
Section: Introductionmentioning
confidence: 99%
“…The results from this study were used as a basis for the development of a L. donovani genotyping methodology in Nepal and permitted an association to be made between the Leishmania genotype and the treatment applied to the patients (Rai et al, 2017). It might also be useful in identifying new drugs against leishmaniasis (Hefnawy et al, 2016). Although these studies have successfully examined intra-species genomic diversity and genes associated with visceral versus non-visceral forms of disease, an analysis of Leishmania genomes associated with different host phenotypes within a species is required to reveal possible sequence signatures or genomic structural markers associated with diverse clinical manifestations or potential host specificity.…”
Section: Introductionmentioning
confidence: 99%
“…parasites with low toxic side effects. Moreover, promising combination therapies are under intense investigation (4,5).…”
mentioning
confidence: 99%
“…O ensaio foi realizado com formas promastigotas de Leishmania amazonensis em fase logarítmica de crescimento. Os parasitos foram semeados em placas de cultivo celular de 96 poços contendo meio Schneider's suplementado, na quantidade de 1×10 6 Leishmania/100 μL de meio. Em seguida as substâncias HDZ-1, HDZ-2, HDZ-3, HDZ-4 e HDZ-5 foram adicionadas aos poços em triplicata e realizadas diluições seriadas, atingindo doze faixas de concentrações (0,0097 a 20 μg.mL -1 ).…”
Section: Determinação Da Concentração Inibitória Média (Ci 50 ) Das Hunclassified
“…A leitura da placa foi realizada num leitor de placas de absorbância -Biotek (modelo ELx800), no comprimento de onda de 550 nm, e os resultados foram expressos em termos de inibição do crescimento (%). O controle positivo foi realizado com 2 μg.mL -1 de anfotericina B (Anf B) diluído em meio Schneider's contendo 1×10 6 promastigotas por poço. Já o controle negativo equivaleu ao meio Schneider's contendo 1×10 6 promastigotas por poço e, neste caso, a viabilidade foi de 100% para o parasito.…”
Section: Determinação Da Concentração Inibitória Média (Ci 50 ) Das Hunclassified
See 1 more Smart Citation